Clinical Observation On The Efficacy Of Chaishao Liujunzi Decoction Combined With Immunotherapy And Anti-angiogenesis In The Treatment Of Advanced Liver Cancer With Liver Depression And Spleen Deficiency Syndrom

Objective:To evaluate the clinical efficacy of Chaishao Liujunzi decoction combined with sintilimab and bevacizumab biosimilar in the treatment of advanced liver cancer with liver stagnation and spleen deficiency syndrome.Methods:According to the inclusion and exclusion criteria,60 patients with advanced liver cancer who were hospitalized in the Oncology Department of Hunan Provincial Hospital of Traditional Chinese Medicine were selected.According to the principle of random grouping,the patients were divided into control group and experimental group according to the random number table.The control group was treated with basic treatment regimen(sintilimab +bevacizumab biosimilar),and the experimental group was treated with basic treatment regimen + Chaishao Liujunzi decoction for 4 courses.The tumor remission,TCM syndrome score,quality of life score,survival status analysis and incidence of adverse reactions were compared between the two groups.SPSS 25.0 software was used to analyze the data.Results:(1)In this study,there was no significant difference in baseline data(gender,age,hepatitis background,liver function Child-Pugh classification,stage,etc.)between the two groups(P>0.05).(2)The main observation indicators: the ORR and DCR of the experimental group were higher than those of the control group,and the difference between the two groups was statistically significant(P<0.05).(3)Secondary observation indicators: first,there was no statistically significant difference in TCM syndrome scores between the two groups before treatment(P> 0.05).There was significant difference between the two groups after treatment(P <0.01).Secondly,there was no significant difference in the quality of life score between the two groups before treatment(P> 0.05).After treatment,the quality of life score of the experimental group was better than that of the control group,the difference between the two groups was statistically significant(P<0.05).Thirdly,the progression-free survival and overall survival of the two groups were not reached.Finally,the overall incidence of AST elevation,serum bilirubin elevation,and thrombocytopenia in the experimental group was lower than that in the control group,and the incidence of grade 3-4 TRAEs was lower than that in the control group,P<0.05,and the difference was statistically significant.Conclusion:In the treatment of patients with liver stagnation and spleen deficiency syndrome of advanced liver cancer,Chaishao Liujunzi decoction and sintilimab plus bevacizumab biosimilar have certain advantages over sintilimab plus bevacizumab biosimilar in alleviating tumor progression,relieving clinical symptoms,improving quality of life and reducing adverse reactions,which can improve the treatment compliance of patients and help to improve the curative effect.